$56.58
3.96% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US00182C1036
Symbol
ANIP

ANI Pharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation

ANI Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
80%
Hold
20%

ANI Pharmaceuticals, Inc. Price Target

Target Price $78.40
Price $56.58
Potential
Number of Estimates 5
5 Analysts have issued a price target ANI Pharmaceuticals, Inc. 2025 . The average ANI Pharmaceuticals, Inc. target price is $78.40. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 4 Analysts recommend ANI Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ANI Pharmaceuticals, Inc. stock has an average upside potential 2025 of . Most analysts recommend the ANI Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 486.82 598.94
53.87% 23.03%
EBITDA Margin 22.46% 25.12%
127.43% 11.86%
Net Margin 4.07% -0.54%
120.03% 113.27%

5 Analysts have issued a sales forecast ANI Pharmaceuticals, Inc. 2024 . The average ANI Pharmaceuticals, Inc. sales estimate is

$599m
Unlock
. This is
7.83% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$600m 8.03%
Unlock
, the lowest is
$597m 7.50%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $487m 53.87%
2024
$599m 23.03%
Unlock
2025
$718m 19.92%
Unlock
2026
$763m 6.29%
Unlock
2027
$802m 5.08%
Unlock
2028
$835m 4.08%
Unlock

4 Analysts have issued an ANI Pharmaceuticals, Inc. EBITDA forecast 2024. The average ANI Pharmaceuticals, Inc. EBITDA estimate is

$150m
Unlock
. This is
115.16% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$151m 116.36%
Unlock
, the lowest is
$150m 114.04%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $109m 249.94%
2024
$150m 37.63%
Unlock
2025
$182m 20.65%
Unlock
2026
$207m 14.09%
Unlock
2027
$227m 9.41%
Unlock
2028
$242m 6.90%
Unlock

EBITDA Margin

2023 22.46% 127.43%
2024
25.12% 11.86%
Unlock
2025
25.27% 0.60%
Unlock
2026
27.13% 7.36%
Unlock
2027
28.24% 4.09%
Unlock
2028
29.01% 2.73%
Unlock

3 ANI Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average ANI Pharmaceuticals, Inc. net profit estimate is

$-3.2m
Unlock
. This is
71.62% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$1.7m 114.85%
Unlock
, the lowest is
$-6.1m 46.32%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $19.8m 130.82%
2024
$-3.2m 116.30%
Unlock
2025
$47.5m 1,570.59%
Unlock
2026
$87.9m 85.05%
Unlock
2027
$114m 29.98%
Unlock
2028
$139m 21.78%
Unlock

Net Margin

2023 4.07% 120.03%
2024
-0.54% 113.27%
Unlock
2025
6.61% 1,324.07%
Unlock
2026
11.51% 74.13%
Unlock
2027
14.24% 23.72%
Unlock
2028
16.66% 16.99%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 0.94 -0.15
130.82% 115.96%
P/E negative
EV/Sales 2.82

3 Analysts have issued a ANI Pharmaceuticals, Inc. forecast for earnings per share. The average ANI Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.15
Unlock
. This is
72.22% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$0.08 114.81%
Unlock
, the lowest is
$-0.29 46.30%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $0.94 130.82%
2024
$-0.15 115.96%
Unlock
2025
$2.25 1,600.00%
Unlock
2026
$4.17 85.33%
Unlock
2027
$5.42 29.98%
Unlock
2028
$6.60 21.77%
Unlock

P/E ratio

Current -104.43 220.74%
2024
-369.00 253.35%
Unlock
2025
25.11 106.80%
Unlock
2026
13.57 45.96%
Unlock
2027
10.44 23.07%
Unlock
2028
8.57 17.91%
Unlock

Based on analysts' sales estimates for 2024, the ANI Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.04 16.03%
2024
2.82 7.37%
Unlock
2025
2.35 16.61%
Unlock
2026
2.21 5.92%
Unlock
2027
2.10 4.84%
Unlock
2028
2.02 3.92%
Unlock

P/S ratio

Current 2.14 9.05%
2024
1.99 7.26%
Unlock
2025
1.66 16.61%
Unlock
2026
1.56 5.92%
Unlock
2027
1.48 4.84%
Unlock
2028
1.42 3.92%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today